Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Douglas A. Treco
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
genetic disorders
rare diseases |
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Inozyme Pharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:leadProductCandidate |
INZ-701
|
| gptkbp:leadProductIndication |
ABCC6 Deficiency
ENPP1 Deficiency |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
calcification disorders
mineralization disorders |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
INZY
|
| gptkbp:website |
https://www.inozyme.com/
|
| gptkbp:bfsParent |
gptkb:Andrey_Zarur
|
| gptkbp:bfsLayer |
7
|